Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.
Marc R. Matrana, MD
Advertisement
Marc R. Matrana, MD, is a medical oncologist and director of Genitourinary Medical Oncology Research at Ochsner MD Anderson Cancer Center, as well as a professor of internal medicine at The University of Queensland Medical School – Ochsner Health.
Articles by Marc R. Matrana, MD
Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.
Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.
Marc R. Matrana, MD, shares his approach to navigating treatment selection when initiating therapy for patients with RCC.
Advertisement
Latest Updated Articles
Dr Matrana on Factors Influencing Upfront Treatment Approaches for RCCPublished: April 18th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5